WO2005065677A1 - Emulsion grasse pour disperser ou dissoudre paclitaxel ou docetaxel - Google Patents

Emulsion grasse pour disperser ou dissoudre paclitaxel ou docetaxel Download PDF

Info

Publication number
WO2005065677A1
WO2005065677A1 PCT/JP2005/000060 JP2005000060W WO2005065677A1 WO 2005065677 A1 WO2005065677 A1 WO 2005065677A1 JP 2005000060 W JP2005000060 W JP 2005000060W WO 2005065677 A1 WO2005065677 A1 WO 2005065677A1
Authority
WO
WIPO (PCT)
Prior art keywords
fat emulsion
acid
group
fatty acid
active ingredient
Prior art date
Application number
PCT/JP2005/000060
Other languages
English (en)
Japanese (ja)
Inventor
Koichi Takeda
Kenji Matsuda
Toshimitsu Terao
Tadaaki Inoue
Original Assignee
Otsuka Pharmaceutical Factory, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Factory, Inc. filed Critical Otsuka Pharmaceutical Factory, Inc.
Publication of WO2005065677A1 publication Critical patent/WO2005065677A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a fat emulsion for dissolving or dispersing at least one active ingredient selected from paclitaxel and docetaxel as well as group power.
  • polysorbate 80 as a food additive is not yet approved in Japan, and its use is problematic in terms of safety.
  • Polyoxyethylene hydrogenated castor oils 50 and 60 are also known to contribute to side effects such as the appearance of anaphylactic shock, and have a problem in safety (Patent Document 2, especially page 1, 22-). See line 30).
  • Non-Patent Document 1 Non-Patent Document 1
  • At least one active ingredient in which a group power including notaritaxel and docetaxel power is also selected can be soluble or dispersed without a problem of crystal precipitation, and safety such as side effects can be improved.
  • solubilization or dispersing agent there is no problem in terms of solubilization or dispersing agent, and solubilization or dispersing technology using such a solubilizing or dispersing agent has not yet been developed.
  • Patent Document 1 JP 08-127529 A
  • Patent Document 2 US Patent No. 5,616,330
  • Non-patent document l Adam, J.D “et al, (1993),” Journal of the National Cancer Institute Monographs ", No. 15, p. 141-147.
  • An object of the present invention is to provide a new solubilizing agent or dispersing agent which can be used for solubilizing or dispersing notaritaxel or docetaxel, and to dissolve or disperse the above drug using the same. It is to provide a technology to make it more sophisticated.
  • the inventors of the present invention have conducted intensive studies, and as a result, have found that the stabilization effective for dissolving or dispersing at least one active ingredient selected from the group consisting of notaritaxel and docetaxel in a fat emulsion is also obtained. And a solubilizing or dispersing agent containing the stabilizing agent (a fat emulsion for solubilizing or dispersing the active ingredient) and using the same to solubilize or disperse the active ingredient.
  • a solubilizing or dispersing agent containing the stabilizing agent a fat emulsion for solubilizing or dispersing the active ingredient
  • the present invention relates to a fat emulsion according to the following item 1-15, a method for producing a fat emulsion containing the active ingredient according to item 16, and a method for producing a fat emulsion containing the active ingredient according to item 17, Use, a container according to item 18, and a method for preventing crystal precipitation of the active ingredient according to item 19.
  • Item 1 Paclitaxel and docetaxel power
  • An agent, wherein the stabilizer comprises:
  • oily components are present at a concentration of 2-20 w / v%
  • Item 3 The phosphatidyl dalycerol, phosphatidic acid wherein the fatty acid esterified to the glycerol moiety of the stabilizer is a linear or branched saturated or unsaturated fatty acid having 10 to 22 carbon atoms Item 3.
  • the fat emulsion according to Item 1 or 2 which is at least one selected from the group consisting of phosphatidylinositol and phosphatidylserine.
  • Item 4 The phosphatidyl dalycerol, phosphatidic acid wherein the fatty acid esterified to the glycerol moiety of the stabilizer is a linear or branched saturated or unsaturated fatty acid having 12 to 18 carbon atoms Item 14.
  • the stabilizer is distearoyl phosphatidyl glycerol, dipalmitoyl phosphatidyl glycerol, dimyristoyl phosphatidyl glycerol, dioleoyl phosphatidyl glycerol, distearoyl phosphatidic acid, dipalmitoyl phosphatidin.
  • Acid dimyristoyl phosphatidic acid, dioleoyl phosphatidic acid, distearoyl phosphatidylinositol, dipalmitoyl phosphatidylinositol, dimyristoyl phosphatidylinositol, dioleoyl phosphatidylinositol, distearoyl phosphatidyl phosphatidyl phosphatidyl phosphatidylinositol At least one of the phospholipids selected from the group consisting of glycerin and dioleoylphosphatidylserine Item 14.
  • the fat emulsion according to any one of Items 1-3, which is also one kind.
  • Item 6 The fat emulsion according to any one of Items 13 to 13, which is distearoyl phosphatidyl glycerol.
  • Item 7 The fat emulsion according to any one of Items 3 to 6, wherein the stabilizer is present in the fat emulsion at a concentration of 0.03-lw / v%.
  • the stabilizer is a phosphatidylethanolamine modified with a polyalkylene glycol, and the fatty acid obtained by esterification to the glycerol portion has a linear or branched chain having 10 to 22 carbon atoms.
  • Item 14 The fat emulsion according to any one of Items 13 to 13, which is at least one kind of a phospholipid derivative that is a saturated or unsaturated fatty acid.
  • the stabilizer is a phosphatidylethanolamine modified with a polyalkylene glycol having an average molecular weight of 1,000 to 5,000, which is esterified to a glycerol moiety to form a fatty acid having 14 to 18 carbon atoms.
  • Item 14 The fat emulsion according to any one of Items 13 to 13, which is at least one kind of a phospholipid derivative that is a linear or branched saturated or unsaturated fatty acid.
  • Item 10 A phospholipid derivative selected from the group consisting of distearoyl phosphatidyl ethanolamine polyethylene glycol 5000, distearoyl phosphatidyl ethanolamine polyethylene glycol 3000, and distearoyl phosphatidyl ethanolamine polyethylene glycol 2000.
  • Item 4. The fat emulsion according to any one of Items 1 to 3, which is at least one of the following.
  • Item 11 The fat emulsion according to any one of Items 8 to 10, which is present in the fat emulsion at a concentration of 0.1-lw / v%.
  • Item 12 The stabilizer according to any one of Items 1 to 3, wherein the stabilizer is at least one member selected from the group consisting of a linear or branched saturated or unsaturated fatty acid having 10 to 22 carbon atoms.
  • Item 13 The stabilizer according to any one of Items 1 to 3, wherein the stabilizer is at least one member selected from the group consisting of a linear or branched saturated or unsaturated fatty acid having 10 to 20 carbon atoms.
  • the stabilizing agent is at least one fatty acid selected from the group consisting of oleic acid, isomyristic acid, isopalmitic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, and arachidic acid.
  • Item 4. The fat emulsion according to any one of Items 1 to 3, which is a seed.
  • Item 15 The fat emulsion according to any one of Items 12 to 14, which is present in the fat emulsion at a concentration of 0.05-2 w / v%.
  • At least one active ingredient selected from the group consisting of paclitaxel and docetaxel is mixed with the fat emulsion according to any one of Items 1 to 15 to dissolve or dissolve the active ingredient.
  • a method for producing a fat emulsion contained in a dispersed state is provided.
  • Item 17 The fat according to any one of Items 1 to 15 for the production of a fat emulsion containing at least one active ingredient selected from the group consisting of paclitaxel and docetaxel in a dissolved or dispersed state. Use of emulsion.
  • Item 18 A container for a fat emulsion containing at least one active ingredient selected from the group consisting of paclitaxel and docetaxel in a dissolved or dispersed state, wherein the container is partitioned by a partition means capable of communicating.
  • a partition means capable of communicating.
  • An active ingredient is contained therein.
  • Item 19 A method for preventing crystal precipitation of an active ingredient in a fat emulsion containing at least one active ingredient selected from the group consisting of paclitaxel and docetaxel, comprising the steps of: A method characterized by mixing with the fat emulsion according to any one of the above.
  • the fat emulsion of the present invention for preparing a stable fat emulsion containing paclitaxel and Z or docetaxel as active ingredients will be described in detail.
  • the fat emulsion of the present invention is a fat emulsion for dissolving or dispersing paclitaxel and docetaxel, and contains the following oily components, an emulsifier, and a stabilizer as essential components.
  • the oil component used for preparing the fat emulsion of the present invention is usually a vegetable oil.
  • the vegetable oil include soybean oil, cottonseed oil, rapeseed oil, sesame oil, corn oil, peanut oil, safflower oil, olive oil, castor oil and the like.
  • the oil component may be a medium-chain triglyceride.
  • Specific examples include various commercially available products such as “COCONARD” (COCONARD TM, Kao Corporation), “ODO TM” (Nissin Oil Co., Ltd.), “Miglyol” (Myglyol TM, SASOL), “Panasate” (Panasate) TM, Nippon Oil & Fats Co., Ltd.).
  • COCONARD COCONARD TM, Kao Corporation
  • OEO TM Dissin Oil Co., Ltd.
  • Miglyol Myglyol TM, SASOL
  • “Panasate” Panasate) TM, Nippon Oil & Fats Co., Ltd.
  • These vegetable oils and medium-chain triglycerides use one species alone They may be used from the same group (vegetable oil or medium-chain triglyceride) or two or more kinds from different groups may be appropriately mixed and used.
  • the oil component is not limited to the above-described vegetable oil and medium-chain triglyceride, and may be, for example, an animal oil, a mineral oil, a synthetic oil, an essential oil, or a mixture of two or more. There may be. Further, these animal oils and the like may be used in combination with the vegetable oil and Z or medium-chain triglyceride.
  • Typical examples of the emulsifier include natural phospholipids such as egg yolk lecithin, yolk phosphatidylcholine, soy lecithin, soy phosphatidylcholine, hydrogenated yolk lecithin obtained by hydrogenating them, hydrogenated yolk phosphatidylcholine, hydrogenated soy lecithin, water Soybean phosphatidylcholine and the like can be mentioned. Further, the emulsifier may be chemically synthesized phosphatidylcholine and phosphatidylethanolamine.
  • the chemically synthesized phosphatidylcholine includes dipalmitoyl phosphatidylcholine, dimyristyl phosphatidylcholine, distearoyl phosphatidylcholine, dioleoyl phosphatidylcholine, and the like.
  • the chemically synthesized phosphatidylethanolamine includes dipalmitoylphosphatidylethanolamine, dimyristoylphosphatidylethanolamine, distearoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, and the like.
  • emulsifiers can be used alone or as a mixture of two or more.
  • preferred emulsifiers are egg yolk lecithin, egg yolk phosphatidylcholine, soy lecithin and soy phosphatidylcholine.
  • the stabilizer is selected from the group consisting of:
  • Fatty acid strength by esterification to the glycerol moiety is a linear or branched saturated or unsaturated fatty acid having 10 to 22 carbon atoms, preferably a linear or branched fatty acid having 12 to 18 carbon atoms.
  • Phosphatidylglycerol, phosphatidyl which is a linear or branched saturated or unsaturated fatty acid At least one phospholipid selected from the group consisting of atidic acid, phosphatidylinositol and phosphatidylserine,
  • a phospholipid derivative which is a linear or branched saturated or unsaturated fatty acid having 14 to 18 carbon atoms,
  • glycol moiety refers to the structure of phosphatidylglycerol, phosphatidic acid, phosphatidylinositol and phosphatidylserine, and phosphatidylethanolamine (the constituent fatty acid is palmitic acid).
  • phosphatidylglycerol phosphatidic acid, phosphatidylinositol and phosphatidylserine, and phosphatidylethanolamine (the constituent fatty acid is palmitic acid).
  • Fatty acids constituting the phospholipid (a) ie, the glycerol portion of the phospholipid (a) is esterified.
  • Examples of the fatty acid constituting the phospholipid derivative (b) i.e., the fatty acid obtained by esterifying the dalicerol portion of the phospholipid derivative (b)
  • the fatty acid (C) include naturally occurring fatty acids. There may be mentioned straight-chain or branched-chain saturated or unsaturated fatty acids which are present.
  • fatty acids include, for example, linear fatty acids such as ricopric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid and eicosapentaenoic acid.
  • linear fatty acids such as ricopric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid and eicosapentaenoic acid.
  • branched fatty acids such as isomyristic acid, isopalmitic acid, isostearic acid, and isoarachidonic acid.
  • the phospholipid (a) containing the above fatty acid as a constituent fatty acid component includes dicaprol phosphatidyl glycerol, dilauroyl phosphatidic acid, dimyristoyl phosphatidyl inosino, dipalmitoyl phosphatidyl serine, distearoyl phosphatidyl glycerol, Diarachidoylphosphatidylglycerol, dibehenylphosphatidic acid, distearoylphosphatidylinositol, distearoylphosphatidic acid, distearoylphosphatidylserine, diisomyristoylphosphatidylglycerol, diisostearoylphosphatidylic acid, diisoarachiditolphosphatidylic acid, etc. .
  • distearoyl phosphatidylglycerol distearoylphosphatidic acid, distearoylphosphatidylinositol and distearoylphosphatidylserine are preferable, and distearoylphosphatidylglycerol and distearoylphosphatidic acid are more preferable.
  • the phospholipid derivative (b) containing the above fatty acid as a constituent fatty acid component more specifically includes a phosphatidylethanolamine modified with a polyalkylene glycol represented by the following general formula (I). [0044] [Formula 2]
  • R 1 and R 2 are linear or branched saturated or unsaturated fatty acids having 10 to 22 carbon atoms, preferably linear or branched fatty acids having 14 to 18 carbon atoms
  • R 3 and R 4 represent a hydrogen atom or a methyl group
  • -X- represents a group -CO (CH).
  • n an integer of 20 to 120.
  • the polyalkylene glycol that modifies phosphatidylethanolamine in the phospholipid derivative (b) is more specifically a substituent (substituted on a nitrogen atom) at the amino group of phosphatidylethanolamine. As a group) through an X group.
  • the polyalkylene glycol is polyethylene glycol or polypropylene glycol.
  • phospholipid derivative (b) examples include, for example, distearoyl phosphatidylethanolamine polyethylene glycol 5000 (SUNBRIGHT
  • each compound indicates the average molecular weight of polyethylene glycol.
  • the average molecular weight of the polyalkylene glycol, such as polyethylene glycol, is preferably in the range of about 1000-5000.
  • each of the compounds exemplified above can be used alone, and each of the compounds in each group can be used. And two or more types can be used together.
  • the compounds belonging to the respective groups of the phospholipid (a), the phospholipid derivative (b) and the fatty acid (c) may be appropriately selected and used in combination. It is possible.
  • the amount of the phospholipid (a) to be incorporated into the fat emulsion of the present invention is more preferably 0.01-lw / v% (the total amount thereof when two or more phospholipids are used in combination, the same applies hereinafter), and more preferably. Should be within the concentration range of 0.03-lw / v%. Utilization in this range can provide a fat emulsion having excellent emulsion stability as expected in the present invention.
  • w / v% representing the blending amount (concentration) of the stabilizer and other components in the fat emulsion of the present invention means each component weight g / volume of fat emulsion lOOmL. I do.
  • the amount of the phospholipid derivative (b) incorporated into the fat emulsion of the present invention is 0.01-lw / v% (when two or more phospholipid derivatives are used in combination, the total amount thereof is the same hereinafter), More preferably, a concentration range power of 0.1-lw / v% is suitably selected. Utilization within this range provides a fat emulsion having excellent emulsion stability as expected of the present invention.
  • the amount of the fatty acid (c) to be incorporated into the fat emulsion of the present invention is 0.05-5 w / v% (when two or more fatty acids are used in combination, the total amount thereof, the same applies hereinafter), more preferably It is appropriate to select from the concentration range of 0.05-2w / v%. Utilization in this range can provide a fat emulsion having excellent emulsion stability as expected in the present invention.
  • the respective components to be used are appropriately selected from the ranges described above. Although it is advantageous to use them together, a synergistic effect can be expected by using these together, so that each of the components used together can be near the lower limit within the above range. Further, in some cases, the amount may be lower than the lower limit.
  • the total amount of the components used together should be selected from the range of a concentration of 0.01-lw / v% in the fat emulsion of the present invention, more preferably from the range of a concentration of 0.01-0.7w / v%. Can be. The desired effect of the present invention is also exhibited by this combination.
  • the present invention has been found for the first time that the use of the above-mentioned specific stabilizing agent enables to obtain a fat emulsion having excellent emulsion stability and high safety.
  • additives can be further added to the fat emulsion of the present invention, if necessary but not particularly required.
  • Such additives are included in this type of emulsion which can be administered by injection.
  • antioxidants include sodium metabisulfite (which also acts as an antibacterial agent), sodium sulfite, sodium bisulfite, potassium metabisulfite, and potassium sulfite.
  • antibacterial agents include sodium caprylate, methyl benzoate, sodium metabisulfite (which also acts as an antioxidant), sodium edetate, and the like.
  • Sodium hydroxide, hydrochloric acid and the like can be used as the pH adjuster.
  • glycerin As the tonicity agent, glycerin; saccharides such as butdu sugar, fructose and maltose; sugar alcohols such as sorbitol and xylitol can be used.
  • those which are oil-soluble can be used by being previously mixed with the oily components constituting the emulsion.
  • the water-soluble additive can be added to and mixed with the water for injection or the aqueous phase of the resulting emulsion.
  • the amounts of these additives are obvious to those skilled in the art, and are not particularly different from those conventionally known.
  • the fat emulsion of the present invention may further contain a cyclodextrin conjugate as needed.
  • the drug to be dissolved or dispersed may be stably soluble or dispersed at a higher concentration.
  • Cyclodextrin conjugates include cyclodextrin, derivatives thereof, and pharmacologically acceptable salts thereof.
  • Derivatives of cyclodextrin include alkyl derivatives of cyclodextrin, hydroxyalkyl derivatives, sulfoalkyl ether derivatives, sugar bond derivatives and the like.
  • the pharmacologically acceptable salts of cyclodextrin and its derivatives include sodium salts, potassium salts, magnesium salts and the like.
  • the amount of the cyclodextrin conjugate in the fat emulsion of the present invention is about 0.01-50 w / v%, preferably the range of the concentration is about 0.02-40 w / v%. .
  • Preparation of the fat emulsion of the present invention is not particularly limited as long as an emulsion is obtained, and can be according to a general method.
  • a typical method is to mix an oil component, an emulsifier, a stabilizer and, if necessary, an oil-soluble additive component, add water for injection to this mixture, coarsely emulsify, and then use an appropriate high-pressure emulsifier, etc. Then, a method of fine emulsification (main emulsification) can be employed.
  • the mixing ratio of the oil component and the emulsifier in the fat emulsion of the present invention is such that the oil component is
  • each concentration of 2-20 w / v% and emulsifier is 0.4-10 w / v%.
  • a particularly preferable mixing ratio can be selected from a range in which the oil component has a concentration of 3-10 w / v% and the emulsifier has a concentration of 0.5-7 w / v%.
  • the mixing ratio of the stabilizer is as described in the above (2). Table 1 below shows the mixing ratios of these components and particularly preferable mixing ratios.
  • the coarse emulsification and the fine emulsification adopted in the above method for example, using a homomixer such as TK homomixer manufactured by Tokushu Kika Kogyo Co., Ltd.
  • the required coarse emulsification means and the fine emulsification means using a high-pressure homogenizer or an ultrasonic homogenizer can be exemplified.
  • the fine emulsification using a high-pressure homogenizer can be generally performed by passing about 2 to 50 times, preferably about 5 to 20 times under a pressure condition of about 200 kg / cm 2 or more.
  • each emulsification operation may be carried out by employing a slight heating operation (for example, 80 ° C. or less, preferably about 40-80 ° C.) which may be carried out at normal temperature.
  • the fat emulsion of the present invention obtained by force is not particularly required, but may be further added with a suitable pH adjuster (acid or alkali) depending on the type of each component to be used to obtain a pH suitable for human administration.
  • a suitable pH adjuster acid or alkali
  • the product is filled in an appropriate container, for example, a vial, a syringe, a plastic bag, an ampule, etc., according to a conventional method, and then sterilized by a usual filtration operation, sterilization operation or the like to obtain a final product.
  • the pH can be adjusted by adding an appropriate acid or alkali as a pH adjuster.
  • Preferred pH ranges to be adjusted include 5.0-9.0, more preferably 6.0-8.0.
  • the pH can be adjusted at any time before and after the emulsification operation for preparing the fat emulsion of the present invention.
  • the filtration operation can be performed using a normal membrane filter.
  • the sterilization operation can be performed by, for example, high-pressure steam sterilization, hot water immersion sterilization, shower sterilization, or the like. More preferably, the sterilization operation includes, for example, a high-pressure steam sterilization operation (eg, 121 ° C., 12 minutes) using an autoclave.
  • the fat emulsion of the present invention is excellent in emulsification stability, and in addition, its viscosity and osmotic pressure can be adjusted to those similar to those of a commercially available nutritional fat emulsion.
  • the thus prepared fat emulsion of the present invention is administered to a patient after dissolving or dispersing at least one active ingredient selected from the group consisting of paclitaxel and docetaxelca into the patient. This can reduce the burden on the patient.
  • the fat emulsion of the present invention can easily dissolve or disperse therein at least one active ingredient selected from the group consisting of paclitaxel and docetaxel.
  • the drug-containing fat emulsion obtained by force is prevented from adverse effects such as crystal precipitation.
  • the fat emulsion can be in a fine and uniform emulsion form, usually having an average particle size of about 0.3 m or less.
  • the present invention provides a method for dissolving or dispersing at least one active ingredient selected from the group consisting of paclitaxel and docetaxelca in the fat emulsion using the fat emulsion of the present invention as described above ( Fat emulsion production method).
  • this method utilizes the fat emulsion of the present invention to dissolve or disperse at least one active ingredient selected from the group consisting of paclitaxel and docetaxel carpa in the fat emulsion. At this time, it can be regarded as a method for preventing the crystal precipitation.
  • This method can be carried out simply by mixing at least one active ingredient selected from the group consisting of paclitaxel and docetaxel with the fat emulsion of the present invention.
  • the above mixture In general, it can be carried out using a mechanical stirring operation. At that time, no emulsification operation is required again.
  • an injection kit preparation such as a double bag type
  • the mixing can be carried out, for example, by opening the partition of the double bag and slightly shaking the bag.
  • the mixing ratio of the fat emulsion of the present invention and the paclitaxel and docetaxel power is selected from the group consisting of paclitaxel and docetaxel power in the final fat emulsion product obtained after mixing.
  • the at least one active ingredient is selected from a range that provides a concentration of about 0.01-0.5 w / v%, preferably about 0.02-0.3 w / v%.
  • At least one active ingredient selected from the group consisting of notaritaxel and docetaxel is also dissolved in various forms available, for example, powdered forms (including powders in the form of hydrates), and appropriate dissolution solutions. Any of a liquid form may be used. Usually, it is preferably used in the form of a solution dissolved in polyethylene glycol (PEG), ethanol, or the like.
  • PEG polyethylene glycol
  • the drug-containing fat emulsion thus obtained is intravenously administered or infused, for example, as an antineoplastic drug in the same manner as a conventional fat emulsion of this kind.
  • the fat emulsion is stable and can be used safely without the risk of separating into two layers, enlargement of fat particles and precipitation of sediment.
  • the fat emulsion of the present invention can be prepared into various forms in which at least one active ingredient selected from the group consisting of paclitaxel and docetaxel can be mixed at the time of use, for example, a kit form for injection.
  • a kit form for injection Specific examples of the kit preparation form include a double bag type, a two-chamber syringe type, and an integrated type (double-ended needle, connecting needle).
  • the preparation into a compact kit preparation for injection can be carried out quickly and accurately, and the prepared preparation can suppress the risk of bacterial contamination and needle stick accidents during compounding in practical use. In addition, it is possible to prevent the particles from increasing even in the current administration using a three-way stopcock.
  • kits formulation include the fat emulsion of the present invention, paclitaxel and And a product (kit product) in which at least one active ingredient selected from the group consisting of docetaxel and group power and a solvent solution thereof are contained in a specific container. More specifically, the kit milk product according to the present invention is contained in a container having at least two compartments (multiple compartments) partitioned by partitioning means (partition walls) which can be opened and communicated during use. In another room, at least one active ingredient selected from the group consisting of paclitaxel and docetaxel power or a solvent solution thereof is housed.
  • the container used for this product is preferably a flexible container, and a specific example of the container is a double bag known in the field of infusion such as hemodialysis fluid. And the like.
  • the double bag can be formed of various flexible plastics commonly used in medical containers and the like. It is preferable that the plastic has gas nolia property. Specific examples of plastics having gasnolia properties include, for example, resins such as polyethylene terephthalate, polyethylene naphthalate, ethylene'butyl alcohol copolymer, polyvinylidene chloride, polyacrylonitrile, polybutyl alcohol, polyamide, and polyester. Can be mentioned.
  • the container used in the present invention has a force constituted by these various resin films or sheets, a force constituted by a sheet or film obtained by depositing silica, alumina or the like on these films or sheets, and a force constituted by these films or sheets.
  • the laminate force is suitably composed.
  • means for forming a multiple chamber in the container include, for example, (1) a method of forming a partition by easy peeling (easy peeling) (JP-A-2-4671; No. -5138), (2) a method of forming a partition by sandwiching the chambers with clips (see Japanese Patent Application Laid-Open No. 63-309263), and (3) various communication means that can be opened in the partition. (See Japanese Patent Publication No. 63-20550).
  • the container described in (1) is particularly suitable for mass production, and the communication operation is easy, so that it is preferable. That is, the partition walls in the container can be easily formed by, for example, fusing a part of the inner surface of the plastic bag-shaped container using a heat seal bar or the like. Further, the seal portion is weak and can be easily opened by pressing.
  • the product of the present invention contains the fat emulsion of the present invention in one room of a double bag as described above,
  • One chamber contains at least one active ingredient selected from the group consisting of paclitaxel and docetaxel or a solvent solution thereof.
  • These medicines can be accommodated through, for example, a chemical liquid filling or taking-out port member provided at the upper and lower ends of the container.
  • the resulting product can then be sterilized by high-pressure steam sterilization using an autoclave according to a conventional method.
  • the partition is opened and the chambers are communicated with each other to mix the two preparations contained in each room to prepare a desired mixed fat emulsion.
  • the mixed fat emulsion is used as an antineoplastic agent, which is an original use of at least one active ingredient selected from the group having paclitaxel and docetaxel strength.
  • Intravenous administration or drip administration can be performed from the above-mentioned drug solution extracting member.
  • Fat emulsions of the present invention (total of 100 mL) having the respective component strengths shown in Table 2 below were prepared as follows.
  • Soybean oil refined soybean oil; Nisshin Oil Co., Ltd.
  • Egg yolk lecithin purified yolk lecithin; Kewpie
  • DSPE-PEG disearoyl phosphatidylethanolamine-polyethylene glyco
  • DSPG Disistearoyl phosphatidyl glycerol, NOF Corporation
  • oily components (soy oil and egg yolk lecithin) were mixed with each component described in Table 2, and
  • a solution prepared by dissolving glycerin in water for injection so that the final concentration becomes 2.21 w / v% is further added thereto, and the mixture is heated under a nitrogen stream using a polytron homogenizer (KINEMATICA) under a nitrogen flow of 25,000.
  • KINEMATICA polytron homogenizer
  • the obtained coarse emulsion was subjected to an emulsification temperature of 40-80 ° C and a nitrogen pressure under a nitrogen stream using a high-pressure homogenizer (APV) until the average particle diameter became ⁇ m or less. It was emulsified at 550 kg / cm 2 .
  • AAV high-pressure homogenizer
  • Example 1 the deviations of DSPE-PEG, DSPG and oleic acid were not added. / ⁇
  • Example G3 when the fat emulsion of the present invention (Example G3) was used, no precipitation of crystals was observed even after 7 days of storage, and the emulsion state was stably maintained. In contrast, when the comparative fat emulsion shown in Comparative Example 1 was used, precipitation of crystals was already observed one day after storage.
  • the present invention it is possible to obtain a stable fat emulsion containing paclitaxel and at least one active ingredient having a group power of docetaxel, and paclitaxel or the like can be obtained as the fat emulsion. If solubilized or dispersed, the resulting fat emulsion can be safely administered to the human body.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un émulsion grasse destiné à solubiliser ou disperser au moins un ingrédient actif sélectionné parmi paclitaxel ou docetaxcel, ledit émulsion graisse comportant un ingrédient huileuse, un émulsifiant et un stabilisateur, par exemple, le phosphatidylglycérol, sélectionné parmi les phospholipides, dérivés de phospholipides, et acides gras. L'invention concerne en outre un procédé pour obtenir un émulsion grasse contenant l'ingrédient actif à l'état d'une dispersion ou une solution, une précipitation de cristaux dudit ingrédient actif étant évitée. D'après ce procédé ledit émulsion est obtenu à partir de l'émulsion grasse.
PCT/JP2005/000060 2004-01-09 2005-01-06 Emulsion grasse pour disperser ou dissoudre paclitaxel ou docetaxel WO2005065677A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004004029 2004-01-09
JP2004-004029 2004-01-09

Publications (1)

Publication Number Publication Date
WO2005065677A1 true WO2005065677A1 (fr) 2005-07-21

Family

ID=34747101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/000060 WO2005065677A1 (fr) 2004-01-09 2005-01-06 Emulsion grasse pour disperser ou dissoudre paclitaxel ou docetaxel

Country Status (2)

Country Link
TW (1) TW200528137A (fr)
WO (1) WO2005065677A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2387991A1 (fr) 2006-02-01 2011-11-23 Adventrx Pharmaceuticals, Inc. Compositions pharmaceutiques stabilisées à succinate de vitamine E, procédés de préparation et utilisation associée
US8470873B2 (en) 2006-02-01 2013-06-25 Mast Therapeutics, Inc. Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
JPH08508046A (ja) * 1993-11-12 1996-08-27 ザ・リサーチ・ファウンデーション・オヴ・ステイト・ユニヴァーシティ・オヴ・ニューヨーク タキソール製剤
JPH09278672A (ja) * 1996-04-12 1997-10-28 Green Cross Corp:The 薬物含有脂肪乳剤
JPH09278673A (ja) * 1996-04-12 1997-10-28 Green Cross Corp:The 薬物含有脂肪乳剤
JPH10502921A (ja) * 1994-07-19 1998-03-17 ヘマジェン／ピーエフシー タキシン類（タキソール）を含んでいる安定な水中油エマルジョンおよびその製造方法
WO2000040236A1 (fr) * 1999-01-04 2000-07-13 Hans Dietl Emulsion sterile et stable contenant des taxanes et son procede de production
WO2002080883A2 (fr) * 2001-03-27 2002-10-17 Phares Pharmaceutical Research N.V. Methode et composition permettant de solubiliser un compose biologiquement actif a faible solubilite dans l'eau

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
JPH08508046A (ja) * 1993-11-12 1996-08-27 ザ・リサーチ・ファウンデーション・オヴ・ステイト・ユニヴァーシティ・オヴ・ニューヨーク タキソール製剤
JPH10502921A (ja) * 1994-07-19 1998-03-17 ヘマジェン／ピーエフシー タキシン類（タキソール）を含んでいる安定な水中油エマルジョンおよびその製造方法
JPH09278672A (ja) * 1996-04-12 1997-10-28 Green Cross Corp:The 薬物含有脂肪乳剤
JPH09278673A (ja) * 1996-04-12 1997-10-28 Green Cross Corp:The 薬物含有脂肪乳剤
WO2000040236A1 (fr) * 1999-01-04 2000-07-13 Hans Dietl Emulsion sterile et stable contenant des taxanes et son procede de production
WO2002080883A2 (fr) * 2001-03-27 2002-10-17 Phares Pharmaceutical Research N.V. Methode et composition permettant de solubiliser un compose biologiquement actif a faible solubilite dans l'eau

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IWASAWA Y ET AL: "Kaimen Handbook", 27 September 2001, NTS, pages: 992 - 997, XP002993708 *
SINGLA A.K. ET AL: "Paclitaxel and its formulations", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 235, 20 March 2002 (2002-03-20), pages 179 - 192, XP002298069 *
WHEELER J. J. ET AL: "Polyethylene Glycol Modified Phospholipids stabilize Emulsions Prepared from Triacylglycerol", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 83, no. 11, November 1994 (1994-11-01), pages 1558 - 1564, XP001016109 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2387991A1 (fr) 2006-02-01 2011-11-23 Adventrx Pharmaceuticals, Inc. Compositions pharmaceutiques stabilisées à succinate de vitamine E, procédés de préparation et utilisation associée
US8470873B2 (en) 2006-02-01 2013-06-25 Mast Therapeutics, Inc. Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof

Also Published As

Publication number Publication date
TW200528137A (en) 2005-09-01

Similar Documents

Publication Publication Date Title
JP4929158B2 (ja) 難水溶性薬物を含有する医薬組成物
JP4212113B2 (ja) サイクロスポリン乳剤
Floyd Top ten considerations in the development of parenteral emulsions
JP7278436B2 (ja) リポソーム組成物および医薬組成物
AU2009280803B2 (en) Stable injectable oil-in-water Docetaxel nanoemulsion
Hippalgaonkar et al. Injectable lipid emulsions—advancements, opportunities and challenges
AU712621B2 (en) Lipid vehicle drug delivery composition containing vitamin E
WO2004052354A1 (fr) Emulsions grasses contenant du propofol
JP2005225818A (ja) パクリタキセル又はドセタキセルの医薬組成物
WO2012133554A1 (fr) Émulsion grasse contenant une prostaglandine
AU778852B2 (en) Parenteral cisplatin emulsion
WO2005065677A1 (fr) Emulsion grasse pour disperser ou dissoudre paclitaxel ou docetaxel
WO2005065676A1 (fr) Emulsion grasse contenant paclitaxel ou docetaxel
Rosoff Specialized Pharmaceutical Emulsions
JP5759804B2 (ja) 容器詰製剤
JP2001131056A (ja) Ｗ／ｏ／ｗ型多相エマルション
WO2000002534A1 (fr) Kit a preparer avant usage avec preparation contenant un medicament et solvant destine a cette fin
JP3611130B2 (ja) 脂肪乳剤の調製方法
Liu Emulsions, Microemulsions, and Lipid-Based Drug Delivery Systems for Drug Solubilization and Delivery—Part I: Parenteral Applications
JP2001151702A (ja) リン脂質親和性薬物を含有する非経口薬剤組成物
JP2012214430A (ja) プロスタグランジン含有脂肪乳剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP